Category: Press Release - Page 71 - Psychedelic Alpha

Read more about the article TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Post published:February 22, 2022
Post category:Press Release

Read more about the article COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

Post published:February 17, 2022
Post category:Press Release

Read more about the article Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Post published:February 17, 2022
Post category:Press Release

Read more about the article Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Post published:February 17, 2022
Post category:Press Release

Read more about the article HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

Post published:February 17, 2022
Post category:Press Release

Read more about the article Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

Post published:February 16, 2022
Post category:Press Release

Read more about the article PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

Post published:February 16, 2022
Post category:Press Release

Read more about the article Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Post published:February 16, 2022
Post category:Press Release

Read more about the article Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Post published:February 16, 2022
Post category:Press Release

Read more about the article atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

Post published:February 16, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.